haemophilia A Archives -

Pfizer and Sangamo have restarted recruitment of patients into their registration trial for haemophilia A gene therapy giroctocogene

Pfizer, Sangamo resume haemophilia gene therapy trial

https://pharmaphorum.com/news/pfizer-sangamo-resume-haemophilia-gene-therapy-trial/

Market Access/ News/ News

Roctavian okay sets up another gene therapy test for Europe

Phil Taylor BioMarin Pharmaceuticals, EU, gene therapy, haemophilia, haemophilia A, regulatory approval, Roctavian 0 Comment

BioMarin Pharma has its landmark first approval for Roctavian – the first for a haemophilia gene therapy –

Roctavian okay sets up another gene therapy test for Europe

https://pharmaphorum.com/news/roctavian-okay-sets-up-another-gene-therapy-test-for-europe/

Market Access/ News/ News

BioMarin gene therapy for haemophilia on course for EU approval

Phil Taylor BioMarin, EU, gene therapy, haemophilia A, regulatory approval, Roctavian 0 Comment

The EMA’s human medicines advisory committee has recommended that BioMarin Pharmaceutical’s haemophilia A gene therapy Roctavian be approved

BioMarin gene therapy for haemophilia on course for EU approval

https://pharmaphorum.com/news/biomarin-gene-therapy-for-haemophilia-on-course-for-eu-approval/

News/ News/ R&D

Sanofi, Sobi eye filings for once-weekly haemophilia A therapy

Phil Taylor haemophilia A, Hemlibra, Roche, Sanofi, SOBI 0 Comment

Sanofi and Sobi’s haemophilia partnership has been under competitive pressure from new therapies like Roche’s antibody Hemlibra, so

Sanofi, Sobi eye filings for once-weekly haemophilia A therapy

https://pharmaphorum.com/news/sanofi-sobi-eye-filings-for-once-weekly-haemophilia-a-therapy/

News/ News/ R&D

Sanofi eyes 2022 filing for haemophilia drug fitusiran, despite safety issue

Phil Taylor Alnylam, Dupixent, Haematology, haemophilia A, haemophilia B, Sanofi 0 Comment

Sanofi’s much anticipated drug for both haemophilia A and B – fitusiran – could be filed in 2022

Sanofi eyes 2022 filing for haemophilia drug fitusiran, despite safety issue

https://pharmaphorum.com/news/sanofi-eyes-2022-filing-for-haemophilia-drug-fitusiran-despite-safety-issue/

Market Access/ News/ News

Scotland’s NHS to fund Roche’s Hemlibra in haemophilia A

Richard Staines Chugai, haemophilia A, market access, Roche 0 Comment

NHS patients in Scotland with haemophilia A are set to get access to Roche and Chugai’s prophylactic injection

Scotland’s NHS to fund Roche’s Hemlibra in haemophilia A

https://pharmaphorum.com/news/scotlands-nhs-to-fund-roches-hemlibra-in-haemophilia-a/

News/ News/ Oncology

Sanofi/Regeneron skin cancer drug among flurry of decisions from EU regulators

Richard Staines cancer, haemophilia A, Novo Nordisk, Regeneron, Sanofi 0 Comment

A new drug for advanced skin cancer and a long-lasting treatment for haemophilia A are among a group

Sanofi/Regeneron skin cancer drug among flurry of decisions from EU regulators

https://pharmaphorum.com/news/sanofi-regeneron-skin-cancer-drug-among-flurry-of-approvals-from-eu-regulators/

News

No US launch until 2020 for Novo’s new haemophilia therapy

Richard Staines haemophilia A, Novo Nordisk, Rare diseases 0 Comment

The US regulator has approved Novo Nordisk’s long-acting therapy for haemophilia A, Esperoct, as the Danish pharma seeks

No US launch until 2020 for Novo’s new haemophilia therapy

https://pharmaphorum.com/news/no-us-launch-until-2020-for-novos-new-haemophilia-therapy/

News/ News/ R&D/ Roche/ US

Roche haemophilia drug gets fast FDA review in expanded use

Richard Staines haemophilia A, Roche, Shire 0 Comment

The FDA has granted ‘Breakthrough Therapy’ status for Roche’s Hemlibra (emicizumab) for people with haemophilia A without factor

Roche haemophilia drug gets fast FDA review in expanded use

https://pharmaphorum.com/news/roches-haemophilia-drug-breakthrough-expanded-use-fda/

Trending

haemophilia A

Login